A Yale Phase 1 trial led by Deepak D’Souza is testing DMT in patients with major depression and in healthy controls, with electrophysiological endpoints built into the design. DMT has trailed psilocybin and MDMA in the formal clinical pipeline, but it is catching up, and its defining property is the one the rest of the psychedelic field is spending money to engineer into other molecules: it is short.

The duration argument

The practical barrier to psychedelic therapy has never been whether the drugs do something to the brain. It is the session. A psilocybin dosing session runs six to eight hours and ties up a clinic room and trained staff for most of a day, which is the single biggest reason the treatment is expensive and hard to scale. The desk has covered the response to this problem on the psilocybin side, where Cybin’s CYB003 is a deuterated psilocin engineered specifically to shorten the trip and make the session cheaper.

DMT does not need that engineering. Its acute effects last minutes to roughly half an hour depending on route, short enough to fit inside a normal clinical appointment. Where the psilocybin developers are working to engineer their way toward brevity, DMT starts there. That is the structural case for DMT as the psychedelic most compatible with how clinics actually operate, and it is the reason the molecule is worth attention even though it entered the formal pipeline late.

The field is moving, not empty

It is worth correcting the impression that DMT has been absent from depression research. It lagged, and now it is accelerating. D’Souza’s own 2022 exploratory study established the safety and tolerability of DMT in healthy volunteers and patients with major depression. In early 2026, a Phase IIa randomized, placebo-controlled trial of a short-acting DMT intervention for major depression reported rapid and lasting reductions in depressive symptoms. Other groups are running vaporized-DMT studies in treatment-resistant depression and intravenous-DMT studies in healthy participants. The new Yale Phase 1 is one entrant in a field that is filling in quickly, not a debut, and the lead programs are already a phase ahead of it.

What makes the Yale trial distinct

The D’Souza study is notable less for its phase than for its instrumentation. It is built around electrophysiological endpoints, using EEG to index the neuroplastic changes DMT induces in both depressed and healthy subjects. That matters for the same reason the desk flagged the cross-species default-mode-network work: the field needs objective measures of whether a psychedelic engaged its target, measures that do not depend on the patient’s subjective report. The functional-unblinding problem, in which participants and raters can tell who received an active psychedelic and that knowledge inflates apparent effects, makes subjective endpoints unreliable. An EEG signature of DMT’s neural effect is a step toward confirming target engagement independent of the experience itself. This is a mechanism-and-biomarker Phase 1, which is what makes it a meaningful precursor rather than another safety checkbox.

Where brevity becomes a question

The short duration is an advantage only if a short experience is therapeutically sufficient, and that is not established. The acute psychedelic experience is widely thought to be part of what drives the antidepressant effect, and a DMT experience that lasts minutes provides a narrow window of it. That is precisely why several DMT programs use continuous intravenous infusion or repeat dosing to extend and control the exposure, which quietly reintroduces some of the session-length complexity DMT was supposed to eliminate. Brevity solves the logistics problem only if the brief version still works.

The rest of the class’s open questions apply unchanged. Effect sizes for psychedelics in depression have been modest, durability is the property that determines real-world usefulness, and unblinding is not solved by a shorter trip, because a rapid, intense DMT experience is, if anything, more unmistakable than a slow one. The EEG endpoints help establish target engagement, but target engagement is not clinical benefit, the same distinction the desk drew around the neural-mechanism research: showing DMT changes the brain in a measurable way is not the same as showing it treats depression.

The frame

The psychedelic field’s central operational problem is the session: how long, how staffed, how expensive. Psilocybin developers are engineering toward shorter experiences. DMT is the molecule that is already short, and that is its core clinical and commercial argument. The Yale Phase 1 is worth watching because it pairs that duration advantage with an attempt to measure the drug’s neural effect objectively, rather than for being early-stage in a field where others have moved ahead. Whether DMT’s brevity turns out to be a feature, enough exposure to produce a durable effect, or a limitation, too little to matter without infusions that rebuild the session problem, is the question the next phase of trials will answer. DMT is the clearest test of whether the shortest path through the session problem actually leads somewhere.